To include your compound in the COVID-19 Resource Center, submit it here.

Bioremediation still not living up to hopes

Slow acceptance of biotreatment systems, perhaps due to limited regulatory pressures, has prompted Celgene Corp. to de-emphasize that line of business and increase its efforts on its chiral chemical business and

Read the full 319 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE